Welcome to our dedicated page for Collplant Biotechnologies news (Ticker: CLGN), a resource for investors and traders seeking the latest updates and insights on Collplant Biotechnologies stock.
CollPlant Biotechnologies Ltd (NASDAQ: CLGN) is a regenerative and aesthetic medicine company whose news flow centers on its recombinant human collagen (rhCollagen) platform, 3D bioprinting activities and medical aesthetics programs. The company regularly issues updates on its rhCollagen-based BioInk products for 3D bioprinting of tissues and organs, tissue repair solutions and aesthetics-focused product candidates.
Investors following CLGN news can expect coverage of financial results reported via quarterly updates, including revenue trends from business collaborators, BioInk sales and tendon repair and wound healing products. CollPlant also reports on clinical and non-clinical milestones for its photocurable dermal and soft tissue filler program, regenerative breast implant development and its collaboration with AbbVie and Allergan on dermal and soft tissue fillers.
Another key news theme is scientific and research collaborations. CollPlant highlights studies such as the Technion – Israel Institute of Technology comparison of its Collink.3D bioink with Matrigel, and Mayo Clinic’s work on a fully humanized 3D bioprinted skin model using plant-derived rhCollagen. These items illustrate how the company’s materials are used in tissue engineering, disease modeling and non-animal alternatives for preclinical research.
Corporate and commercial updates are also frequent, including announcements about expansion of Vergenix STR tendon-repair product distribution in Europe, establishment of a North American logistics center for rhCollagen and BioInk distribution, and participation in industry conferences and investor events. For readers tracking developments in rhCollagen-based biomaterials, 3D bioprinting and aesthetic medicine, the CLGN news page provides an ongoing stream of company-generated information and regulatory disclosures.
CollPlant Biotechnologies (Nasdaq: CLGN) and Stratasys (Nasdaq: SSYS) have initiated a pre-clinical study for 3D-printed regenerative breast implants. The study focuses on 200cc commercial-sized implants produced using CollPlant's rhCollagen-based bioinks on a Stratasys Origin® printer. The innovative implants aim to promote natural breast tissue growth and completely degrade over time, potentially revolutionizing both reconstructive and aesthetic procedures in the $3 billion breast implant market.
The collaboration leverages Stratasys' 3D printing expertise and CollPlant's regenerative medicine technology. Initial results are expected in the first half of 2025. Previous pre-clinical studies have shown promising results, including neovascularization and tissue regeneration without adverse reactions.
CollPlant Biotechnologies (CLGN) and Stratasys (SSYS) have initiated a pre-clinical study for 3D-printed regenerative breast implants. The 200cc commercial-sized implants, made using CollPlant's rhCollagen-based bioinks and printed on a Stratasys Origin® printer, aim to promote natural breast tissue growth and completely degrade over time. This innovation targets the $3 billion breast implant market, offering a potential alternative to traditional silicone implants and autologous fat transfer procedures.
The collaboration focuses on developing a bioprinting solution and scaling up the fabrication process. Initial results from the study are expected in the first half of 2025. Previous pre-clinical studies have shown promising results, including neovascularization and tissue regeneration without adverse reactions.
CollPlant Biotechnologies (Nasdaq: CLGN), a leader in regenerative and aesthetics medicine, has announced its upcoming financial report and conference call for the second quarter of 2024. The company, known for its innovative non-animal-derived collagen technologies, will release its financial statements on Tuesday, August 20, 2024, before U.S. markets open.
A conference call and webcast are scheduled for 10:00 a.m. EDT on the same day. Investors can participate using various dial-in numbers based on their location. A live webcast will also be available in listen-only mode. To streamline the process, CollPlant offers a Call me™ feature for easy access. Investors can submit questions in advance by emailing Dan Ferry at LifeSci Advisors
CollPlant Biotechnologies (Nasdaq: CLGN) has released its first Environmental, Social and Corporate Governance (ESG) and Sustainability Report for 2023. The report outlines the company's initiatives to adopt an ESG strategy focused on high-impact areas. CollPlant aims to enhance plant-based production, reduce emissions, and deliver safe medical solutions.
The strategy is built on three pillars: Impact on the Planet, Impact on People, and Impact on Business Conduct. CollPlant's innovative rhCollagen technology eliminates the need for animal-derived collagen, promoting more ethical and sustainable practices. The company is committed to accelerating the transition to a low-carbon footprint world and enhancing its corporate ESG practices.
CEO Yehiel Tal emphasized that CollPlant's overall strategy is driven by its vision to lead in regenerative medicine and improve global health with its collagen technology. The report serves as a foundation for sharing the company's journey, ambitions, and steps towards a sustainable future in regenerative and aesthetic medicine.
CollPlant Biotechnologies (Nasdaq: CLGN) announced a major milestone with the successful bio-printing of 200cc commercial-size regenerative breast implants using its proprietary rhCollagen bioinks. The company also reported positive interim pre-clinical data from ongoing large-animal studies, showing promising tissue growth and neovascularization without adverse reactions. The implants are designed to regenerate breast tissue, potentially offering a safer alternative to synthetic silicone implants. Large-animal studies are ongoing, with results expected in Q4 2024 and Q1 2025, which will support future human trials and commercialization.
CollPlant Biotechnologies (Nasdaq: CLGN) reported its Q1 2024 financial results and provided a corporate update. The company initiated a new large-animal study for its 3D-bioprinted breast implants in December 2023, expected to conclude in June 2024. Q1 2024 GAAP revenue was $98,000, a decrease from $433,000 in Q1 2023. Costs of revenue increased to $545,000 from $325,000, resulting in a gross loss of $447,000 compared to a gross profit of $108,000 in Q1 2023. Net loss widened to $4.2 million from $3.7 million. The company also highlighted advancements in its Environmental, Social, and Governance (ESG) initiatives and recent patent approvals in the U.S., Brazil, Israel, and Australia. Cash and cash equivalents as of March 31, 2024, stood at $23.2 million.
CollPlant Biotechnologies (Nasdaq: CLGN) announced the release of its financial results for the first quarter of 2024 on May 29, 2024, before U.S. market opening. The company will host a conference call and webcast the same day at 10:00 a.m. EDT to discuss these results and provide corporate updates.
U.S. investors can dial 1-877-407-9716, international investors can call 1-201-493-6779, and Israeli investors can dial 1-809-406-247 using Conference ID 13745964. Participants can avoid long wait times by using the Call me™ feature available 15 minutes prior to the call.
A live listen-only webcast will be available, with a replay accessible on the company's website for a period. Questions for management can be submitted via email to Dan Ferry at LifeSci Advisors up to 24 hours before the event.
Summary not available.
Summary not available.
Summary not available.